This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B . Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol 2006; 1: 685–694.
Franco AF, Martini D, Abensur H, Noronha IL . Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007; 39: 449–452.
Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E . Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17: 215–220.
Augustine JJ, Bodziak KA, Hricik DE . Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369–391.
Oberbauer R, Schena FP, Wali R, Pascoe M, Alberu J, del Carmen Rial M et al. Conversion from Calcineurin Inhibitors to Sirolimus Compared with Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients: 24-Month Safety and Efficacy Results from the CONVERT Trial. Congress of the American Society of Nephrology: San Diego, 2006.
Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C . Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849–2861.
Hochegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C et al. Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008; 19: 1520–1529.
Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565–577.
Aliabadi AZ, Pohanka E, Seebacher G, Dunkler D, Kammerstatter D, Wolner E et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8: 854–861.
Jurado M, Vallejo C, Perez-Simon JA, Brunet S, Ferra C, Balsalobre P et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701–706.
Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531–537.
Barama AA . Mechanisms and management of proteinuria in kidney transplant patients. Drugs 2008; 68 (Suppl 1): 33–39.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hochegger, K., Wurz, E., Nachbaur, D. et al. Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 44, 63–65 (2009). https://doi.org/10.1038/bmt.2008.433
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.433
This article is cited by
-
Glomerular diseases seen with cancer and chemotherapy: a narrative review
Kidney International (2013)